Oncology coordination
The clinical decision is yours; the sourcing, handling, and documentation cross we run on your behalf so the next cycle lands on time.
A growing share of our coordination volume is oncology — particularly accelerated-approval therapies for tumour subtypes that are genomically defined and for which a licensed regional alternative has not yet been approved. The typical situation: a tumour board abroad has identified a driver mutation, the patient meets the US label, and the local oncologist wants to put the patient on the approved US therapy now rather than wait for regional licensure.
The coordination is the same; the clinical considerations are specific
Our operating posture does not change by specialty. What changes in oncology is the density of clinically relevant details we carry on the order: the pathology report that establishes eligibility under the label, the tumour marker result that anchors the rationale, the documentation the regional oncologist will want for their chart, the handling class of the agent, and the timing of the next infusion cycle.
Therapy classes we most commonly coordinate for oncology
- Antibody-drug conjugates — targeted delivery of cytotoxic payloads to tumour cells expressing a specific surface marker (c-MET, HER2, Trop-2, CD22 among others). Cold-chain handling and single-patient accountability are the operational priorities.
- Bispecific antibodies — T-cell engagers for relapsed/refractory lymphomas, multiple myeloma, and solid tumours. Step-up dosing schedules and the first-dose monitoring window are important to the clinical plan.
- Checkpoint inhibitors — PD-1 and PD-L1 blockers across more than thirty tumour-type indications. Subcutaneous formulations (for example, Opdivo Qvantig) simplify delivery but do not change the coordination work.
- Targeted small molecules — kinase inhibitors (EGFR exon 20, KRAS G12C, MET, FGFR, IDH1/2, KMT2A), hormone-receptor modulators, and pathway-specific oral agents. These are often the easiest to handle operationally and the most demanding clinically.
- Rare oncology orphan approvals — for example Modeyso for H3 K27M-mutant diffuse glioma, Revuforj for KMT2A-rearranged acute leukaemia, Avmapki Fakzynja for KRAS-mutant low-grade serous ovarian cancer.
- Emergency oncology antidotes — Vistogard is the only FDA-approved antidote for 5-FU or capecitabine overdose and early severe toxicity; the 96-hour window is the operational priority.
What the treating oncologist keeps; what we coordinate
The treating oncologist remains the prescriber of record, the clinical decision-maker, the party holding the informed-consent conversation with the patient, and the party monitoring response and adverse events. We coordinate DSCSA-compliant sourcing, the named-patient import documentation appropriate to the destination, the cold-chain carrier, and the documentation trail back to the oncologist's chart. Our US-licensed dispensing partner reviews every order and is the counterparty for any dispensing or handling question.
Documentation we typically gather on an oncology order
- Pathology report establishing the eligibility-defining marker (mutation, rearrangement, expression level).
- Prior-therapy timeline sufficient to establish the label-relevant line of therapy.
- Prescribing oncologist's signed order with dose and cycle schedule.
- Treating institution's receipt and handling acknowledgement at delivery.